Globus Medical’s world is about to get a little bigger, as the orthopedic devicemaker moves to acquire Nevro and its ...

Analysts said Nevro’s valuation was “inexpensive,” but the spinal cord stimulation business can benefit from Globus’ scale ...

Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

GlobalData senior medical device analyst says the acquisition could see Nevro’s growth outside the US accelerate.

Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS ... and a mobile charger. The company generates the majority of its revenue in the United States.

The company started 2025 on a solid note, driven by a decent guidance for the year, but a deal for loss-making Nevro creates some discomfort among investors. All this makes me intrigued to watch ...

BTIG says Globus Medical’s (GMED) announced acquisition of Nevro (NVRO) “is surprising on the surface.” Investors did not expect Globus would ...

Nevro NVRO is well-poised for growth in the ... However, concerns regarding softness in the spinal cord stimulation (SCS) market and dependence on third-party payers persist.

Jan. 22, 2015 /PRNewswire/ -- Nevro Corp. (NYSE ... for the Senza spinal cord stimulation (SCS) system. According to the approvable letter, approval of the PMA is subject to satisfaction ...

Globus Medical plans to buy spinal cord stimulation company Nevro for about $250 million, the companies announced on Thursday. Globus will pay $5.85 per share in an all-cash purchase, a 27% ...